Interview: How Medtech Companies Are Preparing To Navigate Post-Pandemic Market
In an interview with Medtech Insight, ZS consultant Brian Chapman explains how medtech companies are handling the uncertainties created by the pandemic and how it could change the industry permanently.
You may also be interested in...
Medtech insiders offer 10 strategies for medtech companies to rethink their businesses right now.
The COVID-19 pandemic is severely hindering patient access to transcatheter aortic valve replacement procedures. Edwards Lifesciences, the market leader, is hopeful that TAVR volumes will recover by the end of 2020, but that will be too late for many patients.
Abbott appears well-positioned to weather the pandemic with continued revenue growth in diabetes, heart failure devices and molecular diagnostics.